ライフサイエンスコーパス: maternal antibody

1 ular responses in the presence or absence of maternal antibody.

2 d efficient transport of functionally active maternal antibody.

3 they are protected from disease, possibly by maternal antibody.

4 ssess high levels of potentially interfering maternal antibody.

5 h maternal antibody than among those without maternal antibody.

6 -9 months of life because of the presence of maternal antibody.

7 be vaccinated against MV in the presence of maternal antibody.

8 irth could prime immunity in the presence of maternal antibody.

9 exes, to overcome the suppressive effects of maternal antibodies.

10 ccur neonatally due to placental transfer of maternal antibodies.

11 ection often relies on passively transmitted maternal antibodies.

12 t structural heart abnormalities and without maternal antibodies.

13 sence and absence of potentially interfering maternal antibodies.

14 d immunity in the presence of high levels of maternal antibodies.

15 ng infants is low because of interference by maternal antibodies.

16 Fc receptors transport maternal antibodies across epithelial cell barriers to p

17 fashion and raises the question of how many maternal antibodies affect brain development or exhibit

18 ibition of vaccine-induced seroconversion by maternal antibodies after vaccination remains a problem,

19 lthough thrombocytopenia, which is caused by maternal antibodies against beta3 integrin and occasiona

20 le prevalence of autism; and the presence of maternal antibodies against fetal brain tissue.

21 s against beta3 integrin and occasionally by maternal antibodies against other platelet antigens, suc

22 esults from the transplacentally transmitted maternal antibodies against Rh factor D and can cause pe

23 Maternal antibodies against the envelope glycoprotein of

24 peared and was attenuated by the presence of maternal antibodies against the virus.

25 To establish that maternal antibody alone and not maternally derived T cel

26 is still immature; however, the presence of maternal antibody also interferes with active immunizati

27 The estimated duration of protection by maternal antibodies among infants in the general populat

28 fant responses to vaccines can be impeded by maternal antibodies and immune system immaturity.

29 during infancy and throughout life, despite maternal antibodies and immunity from prior infection an

30 , passive transfer of MV-specific IgG mimics maternal antibodies and inhibits vaccine-induced serocon

31 ssibly, rubella have lower concentrations of maternal antibodies and lose protection by maternal anti

32 ty of vaccines can be modified in infancy by maternal antibodies and other immunizations.

33 erated after immunization in the presence of maternal antibodies and that the provision of alpha inte

34 rns regarding potential interference between maternal antibodies and the immune response elicited by

35 ildren vaccinated with MV in the presence of maternal antibody and 32.3 per 1000 person-years without

36 However, persistence of maternal antibody and young age affect the quantity of v

37 accine effectiveness, infant protection from maternal antibodies, and loss of immunity following chil

38 urally exposed to maternal allogeneic cells, maternal antibodies, and pathogens.

39 ype may be a pathologic process initiated by maternal antibodies, and persistence of this phenotype e

40 Maternal antibodies are known to suppress the B-cell res

41 IV3 disease must occur in early infancy when maternal antibodies are present, the live attenuated cp4

42 ets and infants are anatomically similar and maternal antibodies are transferred and secreted by a si

43 f maternal antibodies and lose protection by maternal antibodies at an earlier age than children of m

44 GMCs of maternal antibodies at delivery (ELISA units/mL) were 2.

45 l report demonstrating a correlation between maternal antibody binding to epitopes within the carboxy

46 an help to assess the hemolytic potential of maternal antibody, but quantitative measurement of subcl

47 HIV-1 envelope distinct from transplacental maternal antibody by age 12 weeks.

48 Although maternal antibodies can protect against infectious disea

49 These results suggest that maternal antibodies capable of activating AT1 receptors

50 Maternal antibody concentrations and infant age at first

51 The association between GBS maternal antibody concentrations and the risk of neonata

52 ncy Tdap vaccination significantly increases maternal antibody concentrations in consecutive infants.

53 activated polio vaccine, where 2-fold higher maternal antibody concentrations resulted in 20% to 28%

54 Increased maternal antibody concentrations were associated with re

55 antigens, after adjusting for the effect of maternal antibody concentrations.

56 On the basis of the assumption that hPIV3 maternal antibody decays exponentially and constantly, t

57 s were further estimated after adjusting for maternal antibody decline.

58 The low prevalence of maternal antibodies detected in Mexican children against

59 Maternal antibodies did not significantly reduce the eff

60 Thus, maternal antibody did not affect cell-mediated responses

61 In contrast, the presence of maternal antibody did not affect the generation of long-

62 Maternal antibodies directed to pre-F, followed by antib

63 re the same immunity through the transfer of maternal antibodies during lactation.

64 fection in infants due to the persistence of maternal antibodies for a year or more.

65 ss postnatally, despite the clearance of the maternal antibodies from the neonatal circulation.

66 maximal at the time of cardiac ontogeny when maternal antibodies gain access to the fetal circulation

67 rences between mother and father can lead to maternal antibody generation and hemolytic disease in ut

68 Maternal antibody half-life was calculated using infant

69 Because of this, protection by maternal antibodies in infants born to vaccinated mother

70 We demonstrate the presence of maternal antibodies in this system and accurately determ

71 the biologic half-life of human PIV3 (hPIV3) maternal antibody in young infants.

72 ajor players in the ionic mechanism by which maternal antibodies induce sinus bradycardia in CHB.

73 intended for populations with high titers of maternal antibodies (infants in developing countries) ma

74 These data demonstrate that maternal antibodies inhibit B-cell responses by interact

75 Preexisting maternal antibody inhibited infant antibody responses to

76 PUS: oocytes, providing strong evidence that maternal antibodies interact directly with the pore-form

77 The inhibition of vaccination by maternal antibodies is a widely observed phenomenon in h

78 Maternal antibody is associated with a reduced infant re

79 Maternal antibody is the major form of protection from d

80 mechanism(s) responsible for acquisition of maternal antibody isotypes other than IgG are not fully

81 hanism(s) responsible for the acquisition of maternal antibody isotypes other than IgG are not fully

82 ssing the mechanism underlying inhibition by maternal antibodies, it has been suggested that epitope

83 However, if maternal antibodies lead to blunting, incidence increase

84 er among infants in the EPI arm who had high maternal antibody levels for all 3 poliovirus types (P<.

85 Maternal antibodies lowered the final antibody responses

86 We here examine maternal antibody (MA) levels and their association with

87 VRP-based vaccines in other instances where maternal antibodies make early vaccination problematic.

88 val when administered in early infancy, when maternal antibody may still be present.

89 ibody and 32.3 per 1000 person-years without maternal antibody (mortality rate ratio [MRR], 0.0; 95%

90 [PID] 21) with virulent HRV, the effects of maternal antibodies on protection (from diarrhea and vir

91 e candidates in infants and of the effect of maternal antibodies on vaccine efficacy will aid in the

92 at 16 and 18 weeks of age, and the effect of maternal antibody on Salmonella colonization of progeny

93 m by which FcRn may facilitate absorption of maternal antibodies other than IgG.

94 lues were lower for 6-month-old infants with maternal antibody (P=.0001), 6-month-old infants without

95 ibody (P=.0001), 6-month-old infants without maternal antibody (P=.001), 9-month-old infants with mat

96 ody (P=.03), and 9-month-old infants without maternal antibody (P=.006).

97 antibody (P=.001), 9-month-old infants with maternal antibody (P=.03), and 9-month-old infants witho

98 e aqueous microcapsules, was found to bypass maternal antibody passively transferred by suckling to n

99 d reovirus could bypass the normal effect of maternal antibodies, passively acquired by suckling, to

100 arting vaccination at age 6 months and among maternal antibody-positive participants who started vacc

101 Maternal antibodies prevented colonization of the chicks

102 stered to infant macaques in the presence of maternal antibody primes MV-specific T cell responses bu

103 Passively acquired maternal antibodies protect infants from many pathogens.

104 inue to circulate in pigs after the decay of maternal antibodies, providing a continuing source of vi

105 Maternal antibody reduced the efficacy of vaccination of

106 The specificity of the newly acquired maternal antibodies reflected the amino acid sequence of

107 This study estimates the level of maternal antibody required to protect neonates against e

108 No specific maternal antibody response was detected, eliminating the

109 Maternal antibody responses in early pregnancy (mean ges

110 Immunization in the presence of maternal antibodies resulted in the development of a CD4

111 FNAIT arises when maternal antibodies specific for platelet antigens, most

112 edian IgG level was lower among infants with maternal antibody than among those without maternal anti

113 e rates that accounts for passively acquired maternal antibodies that decay or active immunity that w

114 hort-lived, and Th-2 biased responses and by maternal antibodies that interfere with vaccine take.

115 Ferrets without maternal antibody that were vaccinated intranasally (i.n

116 Ferrets with maternal antibody that were vaccinated parenterally with

117 Ferrets without maternal antibody that were vaccinated parenterally with

118 ge had lower mortality than children with no maternal antibody, the MRR being 0.22 (95% CI, .07-.64)

119 bodies in children increased with increasing maternal antibody titer (lytic, chi 21=26, and P<.001; l

120 ental ZIKV shedding and potential utility of maternal antibody titers to corroborate congenital ZIKV

121 tion assay, after adjustment for decrease in maternal antibody titers, were 67% in the 1x10(5) TCID(5

122 not prevent the recurrence of CHB or reduce maternal antibody titers.

123 equal to four-fold higher than the estimated maternal antibody titre and more than or equal to 8 afte

124 of age is unknown and passively transferred maternal antibodies to hepatitis A virus (maternal anti-

125 indicated a significant association between maternal antibodies to herpes simplex virus type 2 glyco

126 Maternal antibodies to pertussis can hamper infant immun

127 Thus, the ability of maternal antibodies to suppress MK growth is a potential

128 Although the transplacental transfer of maternal antibodies to the fetus may convey improved pos

129 Because transplacentally acquired maternal antibodies to the GBS capsular polysaccharides

130 The effect of passively transferred maternal antibody to hepatitis A virus (anti-HAV) on the

131 control persistent infections, and, through maternal antibody, to protect the host's immunologically

132 t epitope masking explains the inhibition by maternal antibodies, too.

133 orary direct protection of the infant due to maternal antibody transfer has efficacy for infants comp

134 sulting in lower levels of serotype-specific maternal antibody transferred to infants, which could re

135 Maternal antibodies transported across the placenta can

136 son of vaccine administration (type 3 only), maternal antibody (type 3 only), and immunization campai

137 i.n.-parenteral immunization of ferrets with maternal antibody using NYVAC-HF (n = 9) produced higher

138 ccinating against measles in the presence of maternal antibody, using a 2-dose schedule with the firs

139 More rapid decay of maternal antibodies was a major predictor of EBV infecti

140 acellular pertussis antigens, 2-fold higher maternal antibody was associated with 11% lower postvacc

141 Maternal antibody was detected in the progeny of vaccina

142 The influence of maternal antibody was still evident in reduced responses

143 To model vaccination in the presence of maternal antibodies, weanling pups born to DENV2-immune

144 Maternal antibodies were affected by placental infection

145 e a mature immune response and who may carry maternal antibodies which inactivate standard vaccines.

146 low passive, protective immunity via suckled maternal antibodies while permitting active oral immuniz

147 TRT and 3 with fetal thyroid suppression by maternal antibodies whose TRT was discontinued at a late

148 The effects of circulating maternal antibodies, with and without colostrum and milk